Daphne Zohar (PureTech)

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

Cash­ing in on the ex­u­ber­ance around Karuna Ther­a­peu­tics and its po­ten­tial block­buster CNS drug, PureTech has sold a chunk of the biotech’s shares to Gold­man Sachs for $200 mil­lion.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters